TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Circulating oxysterols levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: carotid plaque stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: size of the lipid pool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of foam cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: presence of haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of macrophages in lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall density of inflammation in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experience Adverse Events (AEs), Serious Adverse Events (SAEs) and withdrawals due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change from baseline in forced expiratory volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change from baseline in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Without Surgical Re-intervention for Heavy Menstrual Bleeding Due to Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Leg extension/leg-flexion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDRS-R Total Score (Child)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: response rate of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum recovery of the radioactive dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial diastolic velocity E'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in length and length-for-age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight and weight-for-age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of diarrhea and laboratory-confirmed malaria infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma zinc concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of 10-metres walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time Spent in Drug-paired Room
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Change of olfactory brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tympanic membrane mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with subdiaphragmatic infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants experiencing the primary outcome measure
Endpoint domain: Adverse events/effects
Primary endpoint: Functional response
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improved Pain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with therapeutic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: single-dose pharmacokinetics of esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of NMO or MS
Endpoint domain: Mortality/survival
Primary endpoint: Presence and severity of intra-uterine adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bacterial flora at Web spaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacterial load on OT dress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nasal carriers of organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Count/Percentage of Patients Progression-free at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Predicted Overall Survival at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: pain relief as assessed by pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recommended Phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urea, potassium, phosphate and B2M clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety - cardiovascular
Endpoint domain: Adverse events/effects
Primary endpoint: Cell expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serological markers of coeliac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal wall integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and clinical type of dyspeptic disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Safety Profile of TG-1801
Endpoint domain: Adverse events/effects
Primary endpoint: Change in dental plaque score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine Free Urines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-Troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary incontinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diarrhoea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Ulcer Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to defecation after colonic resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in psychological distress HSCL-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in physician-certified absence from work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in microarray gene expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants experiencing dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of all study participants who demonstrate a tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of severe postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Tumour blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-mediated cellular cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Participants Who Experience Subsequent Recurrent Wheezing Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: steady state area under the curve (AUC) of sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under concentration time curve of sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of ANA tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the number of back CT's
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the number of shoulder ultrasounds
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in rate of posterior capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Toe Walking Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Senior Fitness Test - Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Senior Fitness Test - 30s Chair stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hematologic Toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient's compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score obtained in the Clock n'test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immunization coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timeliness of receipt of scheduled immunization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Short-term intestinal eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: headache occurrence and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PedsQL SCDM
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUCins.0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Experiencing Serious and Non Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported frequency of illicit opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of opioid-negative urine specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum number of weeks abstinent from illicit opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICD-10 Mood Disorder Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Articular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of MVC-COV1901
Endpoint domain: Adverse events/effects
Primary endpoint: Period of diarrhea in hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: tumor targeting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiation doses absorbed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of HAMA response
Endpoint domain: Adverse events/effects
Primary endpoint: Time taken to 1st mobilise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients having hysterectomy post-sterilization through hysteroscopic device placement
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients having hysterectomy post-sterilization through tubal ligation
Endpoint domain: Adverse events/effects
Primary endpoint: Major Adverse Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of TXA127
Endpoint domain: Adverse events/effects
Primary endpoint: CA-MRSA vaginal and nasal colonization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of CA-MRSA SSTI infections in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in ROQa composite score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Developing Anti-LY2127399 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Absolute B Cell Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Auditory brainstem response Wave I, III and V latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Auditory brainstem response Wave I, III and V amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: p300 cortical response wave latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: p300 cortical response wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Shigella diarrheal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vrological profile of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunological profile of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healthy pregnancy weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Birth of the baby
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Active elevation of the affected shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Feasibility of the Tai Chi program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the Tai Chi program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dryness
Endpoint domain: Adverse events/effects
Primary endpoint: Peeling
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Tone (Clarity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Brightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Phase II time constant of Oxygen uptake kinetics (VO2τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminution of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline proportion of stuttering in speech sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients with body weight normalization in treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients with eating disorder symptoms at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients in need for a further treatment after the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Children's Revised Impact of Event Scale (CRIES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentration of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: University of Michigan Sedation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy rate after IUI
Endpoint domain: Mortality/survival
Primary endpoint: mean difference in ETDRS distance visual acuity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Failure Rates (Combined Breakage and Slippage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global cognitive function (composite score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in specific cognitive domains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Coefficient of variation of the tidal volume (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coefficient of variation of the respiratory rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coefficient of variation of the inspiratory time (Ti)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coefficient of variation of the electrical activity of the diaphragm (EAdi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coefficient of variation of the maximal inspiratory pressure (Ppeak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prostatic concentration of ertapenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-sectional area of thigh musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cross-sectional area of knee tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients identified with COPD (or CHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass-to-charge Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful implantation of TAAA branched stent-graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in PICF Cytokine Levels (Log pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in GCF Cytokine Levels (Log pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surgical Avoidance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incident and recurrent cancer and metastases
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in volume at first contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who successfully establish mixed chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion who convert to full donor chimeras
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain assessed using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the overall postoperative course assessed using VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prolapse recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in diet profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in function and activity level in subtalar joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain in subtalar osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin absorption and elimination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Harvard Trauma Questionnaire according to DSM-5 (HTQ-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brief Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck's Anxiety Inventory (BAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Craving in the regulation of craving task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aversive feeling in the emotion regulation task
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reaction times in the cognitive task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient survival at six months
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with positive test with a positive PCR for COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Overall Number of patients positive for COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Overall Number of patients negative for COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum-based Metabolites Associated With Bone Deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in miRNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent of periodontal probing sites that bleed upon probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes